REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference

/PRNewswire/ -- Data for Cohort 1 with six months of follow-up from the Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy to be...

Related Keywords

California ,United States ,Rockville ,Rahuln Khurana ,Dana Cormack ,Michaela Klufas ,Chris Brinzey ,Technology Platform ,Technology Platform Licensees ,Retina Research ,Thomas Jefferson University ,Nasdaq ,Northern California Retina Vitreous Associates ,Corporate Communications ,University Of California At San Francisco ,Wills Eye Hospital ,Mid Atlantic ,Clinical Associate Professor ,San Francisco ,Assistant Professor ,Wills Eye ,Platform Licensees ,Regenxbio Inc ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,